PDCD1 and neoplasm: To illustrate the merit of the prognostic model based MSC-score, the efficacy of PD-L1 or PD-1 expression status, tumor-infiltrating lymphocytes (TILs), mutational burden, and immune gene signatures, which previously described as biomarkers for anti-PD-1 treatment, was also evaluated in GSE91061.